Lisata Therapeutics

Historical price data

Lisata Therapeutics is a clinical-stage oncology company focused on improving the treatment of advanced solid tumors through its CendR Platform®, a technology designed to increase the penetration and accumulation of co-administered drugs into tumors. Its lead asset, certepetide (LSTA1), is being evaluated in a broad Phase 2 program across several hard-to-treat cancers, with preliminary data showing promise in metastatic pancreatic cancer. The company operates with a lean, development-centric model and is currently subject to a definitive acquisition agreement by Kuva Labs, Inc. for $4.00 per share, representing a significant near-term corporate transition.

The CendR Platform® is a proprietary technology that activates a specific transport pathway (CendR) in tumors to enhance the targeted delivery and accumulation of co-administered anti-cancer therapies into solid tumors and immunosuppressive cells within the tumor microenvironment.